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Abstract

Gene-environment interactions are central to the expression of obesity. The condition is strongly heritable (ie,
genetic), and most of the variation in obesity levels between countries and between individuals can be
explained by the effects of obesogenic environments on individual genetic susceptibilities. The nature of the
obesogenic environmental influences is not clear in detail, but they correlate closely with measures of
affluence. The causes of variation in genetic susceptibility are also not clearly defined, but their general nature
has become clearer. The failure of genome-wide association studies or large linkage studies to identify or
replicate causative genetic variants, together with the segregation of obesity-related traits in families,
implicates a heterogenetic mechanism in which rare, dominantly or additively expressed genetic variants are
responsible for most of common obesity. The search for rare causative variants continues with some successes,
but those identified contribute very little to the overall burden and, assuming heterogenetics, there are many
more to find. The time when genomic risk factors provide more information than do currently available
markers, such as family history, is a long way off. Genomic studies to date have contributed little, if anything,
to the prevention and treatment of common obesity and its associated disorders. This contrasts with the
obvious and immediate potential implications of the well-established overall genetic basis of obesity, which
have not yet been exploited in the clinical or public health arenas. Genomic studies, which have helped to
define the genetic basis of common obesity mainly by exclusion, will in the future play an increasingly
important role in understanding and managing obesity, but only with parallel studies of the physiological,
behavioral, and economic influences.
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Abstract: Gene–environment interactions are central to the expression of obesity. The condition
is strongly heritable (ie, genetic), and most of the variation in obesity levels between countries
and between individuals can be explained by the effects of obesogenic environments on individual
genetic susceptibilities. The nature of the obesogenic environmental influences is not clear in
detail, but they correlate closely with measures of affluence. The causes of variation in genetic
susceptibility are also not clearly defined, but their general nature has become clearer. The failure
of genome-wide association studies or large linkage studies to identify or replicate causative
genetic variants, together with the segregation of obesity-related traits in families, implicates
a heterogenetic mechanism in which rare, dominantly or additively expressed genetic variants
are responsible for most of common obesity. The search for rare causative variants continues
with some successes, but those identified contribute very little to the overall burden and, assuming heterogenetics, there are many more to find. The time when genomic risk factors provide
more information than do currently available markers, such as family history, is a long way off.
Genomic studies to date have contributed little, if anything, to the prevention and treatment of
common obesity and its associated disorders. This contrasts with the obvious and immediate
potential implications of the well-established overall genetic basis of obesity, which have not
yet been exploited in the clinical or public health arenas. Genomic studies, which have helped
to define the genetic basis of common obesity mainly by exclusion, will in the future play an
increasingly important role in understanding and managing obesity, but only with parallel studies
of the physiological, behavioral, and economic influences.
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According to the World Health Organization projections, by 2015 about 2.3 billion
adults in the world will be overweight and over 700 million will be obese, and economic
costing predicts that obesity-related expenditure in USA will approach US$100 billion
per annum.1 It is now widely, if not universally, accepted that the rising national and
global prevalence of overweight and obesity since the 1980s can be understood as the
effects of increasingly obesogenic environments (OEs), which are correlated with measures of affluence and food availability,2 in genetically predisposed individuals.3,4
Obesity is assessed by the body mass index (BMI, kg/m2) in most epidemiological
and genetic studies, often together with measures of central fat distribution such as waist
circumference because of adverse metabolic and health associations. However, neither
BMI nor other anthropometric measurements are by themselves sufficiently accurate
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or precise as measures of body fatness in cross-sectional
studies.5–8 Further progress in our understanding of the
genetic underpinnings of obesity will depend on, among other
things, the use of more informative phenotypes.
The large number of potential proximal environmental
factors responsible for promoting overconsumption and/or
underexpenditure of energy and their relative importance is
under lively debate (eg, Luke and Cooper, associated commentaries, and response9), but the evidence of a primary role
of food availability and marketing is persuasive for most.2
Preventative public health efforts targeting food consumption
and/or physical activity have not yet been successful10,11 and
can appear weak against the pressure for commercial profit:
eg, the long campaign directed at reducing consumption of
sugar-sweetened beverages while consumption has increased
fivefold since 1950.12 Similarly, individual weight loss programs have had very limited, if any, success as defined by
long-term (.2 year) reduced weight maintenance.10,11,13 Past
pharmaceutical approaches have been equally disappointing,
both in terms of modest treatment effects and unacceptable
side effects.14,15 At present, the most successful treatments for
obesity are surgical procedures, still with limited application
for most obese and overweight people.14,16
The classic twin adoption studies of Stunkard showed
that both fatness and thinness were highly heritable and not
influenced by the adopting family members’ adiposity.17
Numerous genetic studies since, in a variety of populations
and using various measures of adiposity, have been consistent
with those fundamental findings.4 The nature of the genetic
variation responsible for this heritability is becoming clear
even though the particular genetic variants are not. Evidence
of segregation of obesity-related phenotypes in families18–20
and the failure to account for the heritability in genome-wide
association studies (GWAS)3,21 and linkage studies22 strongly
favor a predominant role for rare variants with large effects
expressed under the influence of OE. The physiological
mechanism(s) responsible has/have not been established, but
the genetic and physiological information currently available remain consistent with the neurobehavioral hypothesis
(NBH) proposed by O’Rahilly and Farooqi.23 In NBH, common obesity is the result of widespread genetic susceptibility
to environmental cues related to food intake,18,24 mediated by
appetite-regulating pathways within the hypothalamus. The
mechanisms linking OE to the expression of obesogenic gene
variant effects are not yet clear.
We aim here to review the recent evidence that leads us
to accept the working model of the obesity epidemic summarized above, to discuss the physiological, clinical, and public

220

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

health implications of the model, and to discuss ways in which
future genomic research could enhance our understanding of
causes and potential treatments of obesity.

Obesity phenotypes have not
been adequate in most genetic
and genomic studies
Common obesity
We have clinical and phenotypic modeling backgrounds
but claim no technical or theoretical expertise in genomics.
However, we argue that the outstanding problems in the
genetics of obesity are intimately connected with our areas
of interest and that further progress in genomic studies is
limited by the inadequacies of the phenotypes used in most
studies. The choice of phenotypic markers for expensive,
large-scale genomic studies is usually restricted to anthropometric measures, BMI, and/or circumferences (waist, hip).
Neither these measures nor the simplistic clinical management phenotypes derived from them adequately represent the
level of body fatness,5–8 and their continuing use contributes
to the current uncertainties.6,25
More direct measures of body fatness based on skinfold
thickness, bioelectric impedance analysis,26 dual-energy
X-ray absorptiometry (DEXA), or hydrodensitometry27 have
been used in a limited number of genomic studies without
obvious benefits regarding gene discovery. With the more
direct measures (skinfolds, DEXA, hydrodensitometry),
the high cost, or other logistic requirements of phenotyping
have restricted the applications to relatively small samples.
While bioelectric impedance analysis is cheaper, its confounding by variability in hydration levels degrades its
accuracy regarding body fat content.28,29
The concept of increased adiposity or body fatness
appears intuitively simple but is not easy to define or measure accurately in humans. The direct measures mentioned
earlier might provide effective approaches to measurement
apart from their logistical problems, but even if an accurate
measure of, eg, total fat mass is obtained, it is not clear a
priori how to express it as a biologically meaningful index
of increased adiposity. The common clinical usage of percent body fat cutoffs is arbitrary.30 Analyzing continuous
measures such as the percent body fat or fat mass indices
implies assumptions about how human adiposity affects, or
is affected by, disease processes. Using either BMI or percent
body fat as covariates can lead to erroneous conclusions in a
genetic context.31 One possible approach is the use of multivariate phenotypic constructs obtained from techniques such
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as principal components or factor analysis, which partition
correlations between multiple input variables into latent
factors. These procedures eliminate uncorrelated components
of the input variables, which can reduce error variance and
hence increase statistical power. Similar improvements in
power are expected in other types of multivariate analysis
such as structural equation modeling.32,33 Recently, we
reported such an analysis of body composition data using
factor analysis in a small-scale study (n∼200). We extracted
a factor (Adiposity), which captured more precisely the segregation in families of obesity-related traits than did either
BMI or measured percent body fat.18 However, the detailed
phenotypic characterization required for that particular analysis may be impractical for large-scale genomic studies. The
expected power benefits from multivariate phenotypes are
most apparent when there are strong correlations between
the individual phenotypes, as is the case with many phenotypes obtained in genomic studies of obesity, but this is not
the only requirement for derivation of useful phenotypes. The
aim must be to construct biologically informative phenotypes
which, in principle, could be achieved either by applying
prior knowledge to the development of explicit physiological models composed of measurable variables31 or by careful
consideration of the biological and statistical properties of the
available raw phenotypes.18 It is also important to consider
the origins of the correlations between phenotypic markers,
so as to specify the correct functional forms of the relationships, and especially to avoid correlated errors when choosing
phenotypes for inclusion. For example, in our own study,18
which used a combination of anthropometric and DEXA
measurements, we used log-transformations to accommodate the dimensional relationships between input variables
and avoided inclusion of multiple phenotypes based on the
same primary measurement (eg, fat mass and percent fat) and
therefore sharing correlated errors. These precautions, which
amount to standard requirements for the extraction of reliable
multivariate constructs, have generally not been applied in
multivariate genomic or genetic studies.20,34
The choice of phenotype(s) for genomic studies of common obesity is unresolved. If, as we discuss in the following sections, the potential utility of large-scale association
studies has been exhausted, more expensive phenotypic
measures may be justified in smaller scale case–control or
linkage studies. It seems likely to us that any single phenotypic measure would contain less genetic information than
carefully designed multivariate constructs. For example,
multivariate constructs derived from commonly obtained
anthropometric measurements (weight, height, and, waist–hip
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c ircumferences) may be worth considering. However, we
expect that the additional costs of direct measures of body
fat would be more than repaid by the increased power and
interpretability of the resulting analyses.

Sub-obesity phenotypes
Clinically, obesity and/or overweight are not homogeneous
phenotypes. There are prospects for identifying useful genetic
markers for those at greater or lesser risk of adverse health
consequences of obesity, which would assist in developing
or targeting treatments. There is growing evidence that a
substantial subset of obese individuals (∼25%), defined by a
lack of risk factors for comorbidities, may be protected from
some or all of the adverse consequences of obesity.35 There
is an established association between abdominal, especially
visceral, fat deposition and adverse health consequences at
least partly independent of total adiposity, which may be
under independent genetic influences.36,37 Identification of
genetic determinants of these clinical phenotypes, we submit, depends on the development of genetically informative
quantitative phenotypes using the principles summarized
earlier.

There are no effective nonsurgical
treatments or preventative
strategies for obesity
Despite much nutritional and physical activity research, no
lifestyle regimen has been reported to maintain substantial
weight loss in the long term.38 This result is consistent with
the strong feedback of metabolic and appetite-regulating
hormones to the hypothalamus when weight loss does occur
in the obese,39 a finding consistent with the predictions of the
NBH. Similarly, public health initiatives promoting lifestyle
changes at the population level have been minimally, if at
all, effective in reducing obesity levels.11 There is almost
no other area in drug development that is replete with as
many failures and withdrawals as seen in obesity.40 Current
novel obesity agents include a 5HT2c receptor agonist
(Lorcaserin), a combination of phentermine and extendedrelease topiramate (Qysmia), both of which have modest
treatment effects and side effects of concern to regulatory
agencies41 and a peripherally acting drug (Beloranib, a
methionine aminopeptidase inhibitor) currently in Phase III
trials, so far without major side effects.42 Of those three,
only Beloranib offers a prospect of broad usage, but to
date, results of treatment have only been reported out to
12 weeks. Currently, only bariatric surgery achieves longterm weight loss: by physical restriction (banding), by
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increasing gastrointestinal satiety hormone release (gastric
bypass), and/or by diverting nutrients.43,44
Despite this lack of effective treatments and strategies,
some governments are being advised to consider financial
penalties for obese patients in regard to health insurance,
justified by the belief that obesity is a personal choice.45
In the USA, the National Institutes of Health has funded
the Childhood Obesity Prevention and Treatment Research
(COPTR) consortium formed to prevent obesity in preschoolers and treat obesity in 1,700 13–17 year olds.46 Reports of
recent childhood lifestyle interventions in randomized trials
showed no significant weight effect despite employing the
currently regarded optimum methodology.47 For example,
12-month follow-up of shared care management in 3–10 year
olds in a randomized trial showed no better BMI outcomes
for intervention than untreated controls (intervention effect
−0.1 [−0.7, 0.5] kg/m2).48 Against this background of failure,
the possible emotional impact of frequent measurements
of body size and weight of a child (and mother)49,50 should
not be ignored when considering large-scale projects such
as COPTR.46 It is also not possible at present to determine
which young people are “healthy” obese, and arguably, who
do not require medical intervention for improved metabolic
health.35 In summary, the treatment issue in obesity is the lack
of proven long-term effective treatments at both the individual
and population levels.

Genetic variants contributing to
common obesity are expressed
under obesogenic environmental
influences
Gene–environment interactions are central to the expression of obesity. The rapid rise in prevalence in developed
countries over the last three decades, coupled with the strong
heritability of obesity, allows no other conclusion.51 Obesity
rates continue to rise in developing countries, but are at or
near saturation in developed countries.52,53 While the identity
and strengths of the proximal factors comprising OE are not
agreed upon, it is clear that indices of affluence either within
(eg, socioeconomic status [SES]) or between (eg, gross
domestic product [GDP]) populations can be powerful proxies
for total OE.54–58 The effect of OE by those measures on obesity
levels is not linear, with evidence of saturation in developed in
developed countries56 consistent with reports of diminishing
national trends in some developed countries. The apparent
plateau level of national BMI at high GDP (∼26 kg/m2)56
is well below a notional full expression of clinically defined
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obesity (BMI$30 kg/m2), indicating that substantially
,100% of individuals are susceptible to OE. Within
countries, the situation is more complex.54,55 In multiple
samples from 36 developing countries, a positive effect of
individual SES explained 74% of the within-country variance
in BMI,58 but in developed countries the relationship is often
reversed, with low SES groups showing the highest obesity
prevalence.54,55 The reasons for this apparent reversal of effect
are not clear. Likely contributors include the influence educational level on obesogenic behaviors and negative effects
of obesity on SES.59 There are also methodological issues
regarding confounding variables, particularly associations
between measures of SES and ethnicity. However, in the
most extensively studied, if not necessarily representative,
country60 (USA), the association between one measure of
SES (education) and BMI has weakened over the period
1970–2000.61 It may be that SES now plays a more minor
role compared to the national level of affluence in the most
developed countries.
Measures of affluence explain approximately 50% of
the between-country variance in BMI and approximately
70% of the within-country BMI variance in developing
countries.58 No gene-discovery studies (GWAS or linkage
or candidate) that we are aware of have utilized any markers
of OE as covariates. Omitting such a powerful conditional
determinant from genetic studies, perhaps unavoidable with
the uncertainties of identity and measurement, must lead to
a reduced power to detect genetic associations and to artifactual associations if population stratification, either within
or between countries, leads to confounding between OE and
genetic markers.
The mechanistic link(s) at the molecular level between
OE and obesity development are not clear. The physiological
evidence implicates hypothalamic appetite-regulating pathways with their various sensor and effector systems,23,24 and
the genomic evidence (see “Obesogenic genetic variants”)
still supports the basic structure of the NBH. In this scheme,
reduced (or increased) function in various components leads
to either an increased drive to eat in the presence of OE
and/or, equivalently, a decreased restraint of an appropriate
drive in response to feedback signals. In either case, without
counteracting changes in energy expenditure, the expected
result is maintenance of larger fat stores at a level that either
balances the increased drive with higher feedback signals
or normalizes the feedback signal itself in the dysfunctional
pathway or parallel (redundant) pathways.
There is currently great interest in the possibility that epigenetic changes to gene function could provide a molecular
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link between OE and obesogenic gene variant effects. This
proposed mechanism is a key element in the hypothesis of
the developmental origins of health and disease (DOHaD),
which proposes that a substantial fraction of the rising prevalence of obesity (and other complex diseases) is due to exposures to OE in utero.62,63 Environmental conditions, including
nutrient availability, can epigenetically influence expression
of genes involved in energy metabolism64,65 and at least one
component of NBH (proopiomelanocortin [POMC]66) in
humans. Epigenetic DNA methylation may be enriched and
more variable in obese compared to nonobese humans.67
These and many other studies, predominantly in animal
models, have clearly established the potential of DOHaD, but
much less evidence exists of any substantial contribution to
endemic human obesity. Direct evidence in humans comes
from studies of the effects of maternal obesity on offspring
phenotypes, studies of which are very difficult to design with
appropriate controls; most do not account for the genetic
influences on obesity which will confound any effects of
in utero environment. The strongest human evidence is in
a series of studies of the effects of maternal bariatric surgery on obesity in children, using a within-subject design
(pre- and post-surgery) to control for genetic influences.
Children conceived after surgery had substantially lower
levels of various obesity-related phenotypes compared to
those conceived before surgery68 and showed an altered
DNA methylation pattern in white blood cells.69 However,
there are reasons to doubt that these findings are applicable
to endemic obesity. Both studies used morbidly obese subjects (BMI ≈46 kg/m2) undergoing the most drastic form of
bariatric surgery (biliopancreatic diversion) which resulted
in massive weight loss (BMI ≈30 kg/m2), which itself results
in nutritional deficiencies in utero.70 The incidence of folate
deficiency is a particular concern for the interpretation of
the DNA methylation pattern.62 In contrast, a large hospitalrecords-based within-subject study of the effects of much
less severe, purely restrictive bariatric surgery (BMI change
from 36 kg/m2 to 32 kg/m2) found no evidence for reduced
adiposity in children conceived after surgery, with trends
in the opposite direction.71 Other studies were designed to
isolate any nongenetic effect of maternal adiposity by use
of maternal FTO genotype as an instrumental variable72 or
by comparing influences of maternal and paternal adiposity
on offspring adiposity.73 Both studies concluded that any
maternal effect on offspring adiposity is weak and unlikely
to explain any substantial fraction of the obesity epidemic.
So while DOHaD and its proposed epigenetic mechanisms
are based on undoubtedly exciting emerging biological
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insights, we found no persuasive evidence for an important
role of DOHaD in endemic human obesity.

Heritability and mode of inheritance
of obesity susceptibility
Obesity is highly heritable, but estimates of the degree
of heritability have varied substantially between studies
(h2∼40%–80%). The source(s) of this variability have not
been established, but a leading candidate is the effects of
variations and trends in OE. For example, twin studies generally give higher heritability estimates than do sibling studies
or multigenerational family studies, perhaps because OE is
likely to vary less between twins than between generations or
siblings of different ages.19 Similarly, as obesity levels have
risen over time in response to rising OE, so have the measured
genetic contributions to the overall variance, and hence h2.74
Many studies have detected evidence of segregation and/or
multimodality of adiposity-related traits but the implied
modes of inheritance have varied. Early studies (reviewed
in Price et al19) found evidence of recessive expression of
higher adiposity, while more recent studies have tended to
favor dominant or additive models of expression.18–20 As
argued by Price et al,19 part of this variation may be due to
secular trends in gene–OE interactions,74 which have the
effect of simulating recessive inheritance in multigenerational
studies. The use of extreme obesity phenotypes would also
tend to favor a recessive pattern if the true mode is additive and the heterozygous phenotype is either obscured by
definition75 or is indistinguishable in the data.76,77 The use of
inappropriate phenotypes can also obscure signals of dominance or additivity. Our own demonstration of segregation of
Adiposity in families with type 2 diabetes mellitus (T2DM)18
was obtained only with a multivariate phenotype based on
direct measures of body compartments (Figure 1A), and
was obscured in body fat percent and BMI data (Figure 1B),
despite the close correlations between Adiposity and body fat
percent or BMI (R2=0.87, Figure 1C). The genetic information is contained within the apparent noise in Figure 1C. In
summary, published studies are either not inconsistent with,
or give explicit support to, dominant or additive expression
of genetic susceptibility to increased adiposity. Because of
its use of an informative and biologically plausible phenotype and a highly enriched sample (family history positive
compared to a carefully matched family history negative
control group) from a developed (OE-saturated) country, and
despite its small sample size (n=202), we submit our study18
as the best current indicator of the mode of inheritance of
susceptibility to common obesity.
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Figure 1 Distributions of age- and sex-adjusted obesity-related phenotypes in
healthy adults with a family history of T2DM (FH+, n=80).
Notes: (A) A latent factor (Adiposity) derived by rotated factor analysis of body
composition and anthropometric data. (B) Residual log-transformed BMI (Adiposity
and loge BMI are both presented as residuals from age and sex models). Data were
binned by deciles of the full sample (FH+, FH-, n=202) and fitted to a bimodal normal
distribution. The dashed line in (A) represents the fitted distribution of Adiposity
(no fit was obtained in the loge BMI data). The segregation of Adiposity in FH+ is
consistent with dominant expression of rare risk variants with major effects, which
are expressed in over half of FH+ and which can account for most of the T2DMassociated obesity in this population. (C) Relationship between Adiposity and BMI
in healthy individuals with or without a family history of T2DM (n=202).18 The line
represents the fit of Adiposity to log-transformed BMI (r2=0.87). Reproduced from
Jenkins AB, Batterham M, Samocha-Bonet D, Tonks K, Greenfield JR, Campbell LV.
Segregation of a latent high Adiposity phenotype in families with a history of type
2 diabetes mellitus implicates rare obesity-susceptibility genetic variants with large
effects in diabetes-related obesity. PLoS One. 2013;8:e70435.18
Abbreviations: T2DM, type 2 diabetes mellitus; BMI, body mass index.

The bimodal distribution of Adiposity in individuals
with a positive family history of T2DM (FH+, Figure 1A) is
consistent with segregation in families of rare obesity susceptibility variants with major effects, contrary to the predictions
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of a polygenic model in which variants at many loci have
cumulative, small effects on the phenotype. Previous studies of the transmission of obesity-related phenotypes have
also generally not favored the polygenic model. However,
a recent simulation study based on extensive identity by
descent and BMI data in families reaches the conclusion
that polygenic inheritance of BMI is capable of explaining
the failure of replication of hits in linkage studies, possibly
by random sampling of chromosomal blocks containing
multiple obesogenic variants of small effects, and therefore
questions the conclusion that a heterogenetic model is favored
by the exclusion of competing hypotheses.78 Their conclusion is based on the equivalence of various polygenetic and
heterogenetic models, rather than on statistical evidence
favoring any particular model. They prefer the polygenic
model for reasons of parsimony, although it seems to us the
least parsimonious of their mechanisms. The heterogenetic
models tested were very stringently defined in terms of
private variants in each family, ie, a minor allele fraction
(MAF) of ∼0.01% vide the usual definition of rare (MAF
,1%) based on the current power of GWAS.79 Whether the
result could apply to more realistic situations in which, for
example, interactions between genes and environment were
considered and the heterogenetic model was less stringently
defined is not yet clear, and we take the current evidence for
segregation of obesity-related phenotypes to strongly favor
the heterogenetic model.
Our analysis18 was insensitive to the nature of the inherited obesogenic variants, but we can conclude that they are
rare to have escaped detection in large-scale studies even
of BMI, even allowing for confounding by OE, and must
have large effects to account for the separation between
modes of Adiposity (0.93 standard deviation units [SD]).
The two factors extracted by Tayo et al,20 which are likely to
partition the variance in Adiposity, show similar effect sizes
(0.84–0.89 SD). The BMI equivalent of the effect size in
Adiposity is approximately 4 kg/m2, and other segregation
studies have reported similarly large effects although direct
comparisons are hindered by the variety of phenotypes
analyzed (BMI,19 fat mass,80 percent body fat,81 skinfolds82),
the different populations sampled, and the genetic models
tested (additive, dominant, mixed). Our major effects
accounted for 91% for the age- and sex-adjusted Adiposity
variance, but this high value is a function of the enrichment
of susceptibility in our sample (positive family history) as
well as the high national GDP and hence OE. The residual
variance (9%; 95% CI, 4%–69%) contains the effects of
all other determinants of Adiposity including polygenes,
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the environment, and interactions between them. While
the point estimate indicates minimal contribution from all
these sources in our sample, the wide confidence intervals
(probably related to small sample size) do not rule out a
substantial contribution in this or other samples. However,
taken with the other estimates of heritability of obesityrelated phenotypes and their strengths and limitations
referred to above, our result supports a predominant role
of segregating rare variants in the transmission of obesity
susceptibility.

Obesogenic genetic variants
The genetic determinants responsible for endemic obesity
remain largely undiscovered. Over 50 loci have been associated with BMI and/or categorical obesity in GWAS and
meta-analyses,3,21,83 but the combined (additive) effects of
all variants account for only a small fraction of the phenotypic variation (1%–2%), leaving most of the heritability
unexplained. Possible sources of this missing heritability
have been well discussed by Hebebrand et al25: nonspecific
phenotypes, measurement error, small effects sizes, rare
variants, inflated heritability estimates, developmental
aspects, gene–gene and gene–environment interactions, to
which we add common copy number variations (CNVs).
While GWAS have not systematically targeted CNVs,
a recent study of linkage disequilibrium between common
single nucleotide variants (SNVs) and common CNVs concluded that “[...] for complex traits, the heritability void left
by genome-wide association studies will not be accounted
for by common CNVs.”84 While all of those sources of error
no doubt contribute to the current heritability void, the
evidence of segregation of obesity-related traits points to a
predominant role of rare variants or a heterogenetic model
of transmission. Under a heterogenetic model, estimates
of heritability are not a useful way of combining evidence
from gene-discovery studies, and it is more instructive
to examine the effect sizes attributable to identified gene
variants. Figure 2 illustrates the distribution of effect sizes
(when reported in or readily transformable to BMI units,
n=47); GWAS-identified results are extracted from recent
reviews3,21,83 or the studies referred to therein. The sources
of the effect sizes of other variants identified in various
candidate designs are discussed in points “1. FTO” to
“7. 16p11.2”. Compared to our estimates of the segregating
effect size (4.1 kg/m2),18 most effects, including all identified in GWAS, are vanishingly small and can be ruled out as
contributors to segregation, although they, and other similar
but unknown loci, presumably contribute to the background
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Figure 2 Boxplot of published heterozygote effect sizes (when reported in or
transformable to BMI units) of obesity-associated genetic variants (n=47).
Notes: The box represents the median and interquartile range and the whiskers
extend to 1.5 times the interquartile range. The box and whiskers enclose all variants
identified in genome-wide association studies except FTO. The red arrow indicates the
BMI effect size calculated from our study of the segregation of Adiposity.18
Abbreviations: BMI, body mass index; POMC, proopiomelanocortin.

variability. The exclusions should include FTO variants if
based on effect size alone, but as we discuss in “1. FTO”,
their emerging mechanism of action may provide a model
for other larger effects in the same region. Also, most GWAS
effects on BMI are so small that there can be no confidence
that they represent effects on body fat as opposed nonfat
compartments. That leaves only the outliers in Figure 2 as
candidates for the types of variant that could contribute to
a segregation signal.
1. FTO: common single-nucleotide polymorphisms (SNPs)
in the FTO region have the largest effect size of any variants detected in GWAS, but that effect (0.4 kg/m2) is too
small to make a significant contribution to the segregation
signal that we and others detect. However, it may be that
other rarer variants in the same region could contribute,
and recent advances regarding the mechanisms of action
of the FTO variants provide a model that exemplifies
the potential of the NBH. Obesity-associated sequences
within FTO are functionally connected through noncoding RNA with an increased expression of the homeobox
gene IRX3, deletion of which results in reduced fat mass
in mice.85 Studies in humans have found associations
between obesity-associated FTO variants and levels of the
satiety hormone leptin (negative),86 the hunger hormone
ghrelin (positive),86,87 and brain responsivity to food cues
(positive).87 So while common FTO SNPs do not contribute
substantially to common obesity susceptibility, they do
illustrate the potential of other rarer variants affecting the
same processes.
2. AMY1: CNVs in AMY1 encoding salivary amylase have
been associated with variations in BMI (low copy number associated with higher BMI) in two independent
samples.88 The effect size plotted in Figure 2 (0.75 kg/m2)
is based on the maximum possible negative difference in
copy number (-5) from the mean of the normal-weight
distributions in Falchi et al.88 This effect size is small
compared to our estimate,18 but could contribute to a
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segregation signal in larger scale studies. The CNV in
AMY1 was investigated in relation to BMI after an initial
screen of effects on gene expression in adipose tissue,88
but the salivary amylase product is also expressed in saliva
under the influence of copy number89 and in various other
tissues. The mechanisms linking AMY1 expression and
BMI have not been established, but AMY1 is known to
have a role in sensory perception of starch in foods as
well as being regulated by autonomic nervous system
(ANS) activity,90 providing potential links to and from
hypothalamic appetite-regulating centers and therefore
possible consistency with the NBH.
3. SIM1: SIM1 is a homologue of a transcription factor in
mice, which is known to be involved in the development
of hypothalamic appetite regulation centers, and haploinsufficiency results in a hyperphagic obesity in mice
and humans. Common SNPs in and near SIM1 regions
were associated with BMI in a candidate gene study in
Pima Indians.91 The risk alleles were common in Pima
Indians (∼0.6), but less so in Europeans (∼0.3) with no
association with BMI in the European sample. Perhaps
linked functional variants have originated in or become
enriched (through genetic drift or selection) in Pima
Indians. The potential mechanism is clear, and consistent
with the NBH, and the effect size (2.2 kg/m2) would be
detectable in a reasonably powered linkage study.
4. CTNNBL1: multiple SNPs mainly in intronic regions of
CTNNBL1 were associated with BMI and fat mass in a
sample of unrelated US Caucasians and were supported
in a French Caucasian case–control study of categorical
obesity,92 but not in a central European sample93 or a Danish
sample.94 Failure of replication is an expected feature of
a heterogenetic model in which different populations or
smaller groups (down to families) could be expected to
have different genetic origins of obesity susceptibility. The
effect size of 2.7 kg/m2 would be detectable in a reasonably
powered linkage study, but there are reasons to doubt the
specificity of the continuous phenotypes for body fatness.
Liu et al92 used directly measured fat mass as a control on
the BMI analyses, but did not control for effects of body
size on fat mass, and so both phenotypes contain information about nonfat body compartments. Consistent with this
potential confounding, the replication study by Andreasen
et al94 found no association with BMI, but significant associations with weight and height. CTNNBL1 variants may be
associated with increased risk of obesity, but the measured
effect size on BMI includes an unknown but probably
substantial contribution from genetic effects on body size.
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Confirmation using an unbiased phenotype is needed. The
functions of CTNNBL1 are not established, and there is no
clear potential link to the NBH, but it is expressed in at least
one region of the human central nervous system (CNS)
(cortex) and variants have been associated with measures
of CNS function (memory).95
5. POMC: POMC is a complex pro-peptide, the products of
which are secreted by neurons that are critically involved
in appetite regulation. Congenital deficiency of POMC is
the cause of a rare form of monogenic obesity, and haploinsufficiency of POMC is linked to increased BMI in
affected families.96 The effects of POMC deficiency were
important elements in the development of the NBH.23
The heterozygote effect size in Figure 2 (3.7 kg/m2) is
an approximation based the original report in SD units
(+1.3) multiplied by the average SD in males and females
(2.85 kg/m2) in the reference data97 used by Farooqi
et al.96
6. LEP and LEPR: leptin acting through the leptin receptor
functions as a feedback signal from adipose tissue fat
stores with strong suppressive effects on appetite through
the hypothalamic leptin–melanocortin signaling pathway.
Both homozygous leptin and leptin receptor deficiencies
cause rare monogenic severe obesity in humans driven
by hyperphagia, and both are crucial elements in the
development of the NBH. Heterozygous loss-of-function
variants in both genes are associated with substantial
effects on body fatness.98,99 In both cases, the phenotype
affected was directly measured by body fat percent
adjusted for age, sex, height, and weight, and the effects
were substantial: +20% body fat for LEP98 and +6% for
LEPR,99 which roughly translate to effects in BMI units
in our sample18 of +9 and +3 kg/m2, respectively.
7. 16p11.2: independent associations with obesity of large
deletions at two locations in 16p11.2 have been detected
following a strategy of resequencing at loci known to be
associated with rare forms of extreme obesity,100,101 and
one of the locations was replicated using continuous
BMI in a population sample101 represented in Figure 2.
The BMI effect size in Figure 2 is based on a very small
sample (4) of heterozygous carriers in that one population, but the combined effect on BMI in all populations
sampled was +1.1 SD units (n=8), similar to our effect
size on Adiposity (+0.93 SD).18 The responsible causal
loci are not clear, but the deleted region contains SH2B1,
which has established links to hyperphagia and obesity
in humans and animals acting through leptin signaling
pathways102 consistent with the NBH.
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As judged by effect size, only the POMC, LEP, and LEPR
heterozygous loss-of-function mutations and the deletions at
16p11.2 stand out as possible examples of the types of variants
which could contribute to a heterogenetic mechanism of susceptibility to common obesity, although contributions from the
others cannot be excluded (except perhaps CTNNBL1). While
we do not suppose that the outlier loci identified in Figure 2
are necessarily representative of all causative variants, it is
noteworthy that their mean effect size (+3.9 kg/m2) is very
close to our estimate of average effect size (+4.1 kg/m2).18 The
gene products of the first three have key roles in appetite regulation, as does one candidate for the 16p11.2 effect, and as do
other gene products identified as causative agents in severe
monogenic obesity (PSK1, MC4R, SIM1).21 Other causes
of severe (syndromic) obesity associated with generalized
developmental CNS disturbances are also linked to disruption
of appetite regulation (Bardet–Biedl syndrome, Prader–Willi
syndrome, pseudohypoparathyroidism, WAGR syndrome).21
When taken together with our evidence of increased sensitivity to food-related cues in healthy family-history-positive
individuals,24 the genomic evidence continues to point to
hypothalamic appetite regulation pathways as the most likely
location of rare variants driving the susceptibility to obesity in
response to increased OE as proposed in the NBH. The effects
of common variants in FTO illustrate how such mechanisms
can operate, and have increased interest in the potential roles
of noncoding RNAs.
The search for rare variants with large effects on obesity susceptibility is in progress and has resulted in some
success,101 as have related approaches in other complex
diseases.103,104 However, the contributions of the newly identified variants to population susceptibilities are very small,
and if, as we conclude, most of the obesity susceptibility
is due to rare variants, there are many more to find. There
are formidable problems in design and statistical analysis
to be solved before identification of rare variants becomes
a routine procedure, and we may currently be able to find
only the “low-hanging fruit” that are amenable to current
techniques.101 The variants’ effects must be large, and it
might therefore be hoped that simple phenotypes such as
BMI would be adequate for reliable discovery, more so than
in GWAS where the small effect sizes must be interpreted
with caution due to biases in BMI. However, even large
effects can be generated or obscured by BMI bias; measured
biases in different ethnic groups range from -6 kg/m2 to
+4.5 kg/m2 at equivalent body fat percentage105,106 and in our
ethnically unselected sample from -3.6 kg/m2 to +6.7 kg/m2
(95% CI -3.1, 4.3) at equivalent Adiposity (Figure 1C).18
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There is a clear need for more informative phenotypes in
these studies.

Implications of a heterogenetic
mechanism for gene discovery,
treatment, and prevention
GWAS studies have reached
their potential
The results obtained from GWAS studies have excluded a
major causative role for common genetic variants in obesity,
directly for common SNPs and indirectly for common
CNVs.84 The GWAS design does not have the power to detect
rare causative variants in any feasible sample size. Power and
accuracy would undoubtedly be improved by the use of better
phenotypes than BMI, but it is unlikely that the improvements would be enough to capture many rare variants. The
increased costs associated with better phenotyping would be
better used in smaller scale studies following the types of
approaches recommended by Walters et al.101

Many variants may produce similar
effects on obesity-related traits
Under a heterogenetic model, the separation between modes
of Adiposity in Figure 1A represents the average effect size
of the causative variants. Our analysis treats it as a fixed (ie,
constant) effect, and while we were unable to model the range
of dispersion of effects, nor any heterogeneity of background
variability, the data are consistent with a very narrow range
of effect sizes superimposed on a constant background variability. It might be thought implausible that many heterogenetic variants could all result in similar effects sizes, but
it is possible for that pattern to arise from the properties of
the affected physiological system(s). For example, the NBH
proposes that appetite regulation systems in the hypothalamus
are the target of most obesogenic variants; those systems are
very complex involving a large number of sensory, effector,
and integrative processes, all interacting with and subject to
feedback from other central regulatory systems such as the
ANS, and affected by systems modulating mood and other
behavioral traits. The overall properties of this system, or
network, of sensors, integrators, and effectors are not clearly
understood, but it is likely that it exhibits features of redundancy in that a complete or partial failure of any component
is partly compensated for by the remaining intact links (an
analogy can be found in the properties of the glucoregulatory system107). Such a system could produce the segregation
behavior that we and others observe.
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Can phenotypic convergence help
to locate new therapeutic targets?
Under some possible structures of the physiological system(s)
involved, there could be clustering of the effects of multiple
variants on potentially targetable subsystems. However,
appetite regulation is such a central process with links to
and from many other systems (ANS, mood, etc) that it makes
specific targeting without undesirable side effects potentially
very difficult, as can been seen in the history of drug development in this area.40 Recent interest in the melanocortin-4
receptor as a potentially targetable component of the NBH
appears to be an illustration of continuing problems of this
nature. Antagonist compounds to melanocortin-4 receptor
are being developed for targeting depression and anxiety,108
while agonists are being developed to target obesity.109 This is
reminiscent of the history of Rimonabant, a drug developed
to target obesity though antagonism of cannabinoid receptors in satiety pathways but which was withdrawn due to
side effects on depression.40 An improved understanding of
the properties of the appetite-regulating system as a control
system could affect strategies for targeting. If, for example,
the system is strongly hierarchical with lateral connections
to other systems such as the ANS mainly at high levels in the
hierarchy, that could be quite different in its implications from
a more distributed network-like structure with many lateral
connections. If a hierarchical structure could be defined,
there may be obvious potential targets at the mid-level in the
system, below the lateral links. A network structure presents
a much more challenging problem.

Similarities and differences in
obesity susceptibility in populations
Obesity and overweight vary between populations due to
effects of and interactions between genetic and environmental factors. Some small genetically isolated populations
have developed very high prevalences of obesity in response
to recent environmental changes (eg, Pima Indians, 110
Nauruans, 111 Australian Aboriginals 112). There are also
marked, though usually less extreme, differences in obesity
prevalences between large national populations,113 which,
as discussed earlier, can be assigned mainly to the effects of
OE on genetically susceptible individuals. The genetic determinants of the variation in susceptibility between individuals
or groups are not clear, except for a very small number of
individuals with severe monogenic obesity. There are currently no known genetic variants or combinations of variants
that are helpful as indicators of risk, in either individuals or
populations. Genetic risk scores calculated by adding known
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obesogenic variant loads have minimal predictive power.114
A very rough calculation based on current estimates of effect
sizes (Figure 2) indicates that approximately 40 different variants per individual would be needed to account for obesity
risk using a multiplicative (epistatic) model.
The origin of the undefined heterogenetic variation
responsible for the varying phenotypic responses to OE is
also unclear. Plausible theories include the effects of positive or negative selection, or of genetic drift, the pros and
cons of which have been extensively discussed115–117 without
resolution. A strong case can be made for selection, which
brings together many features of obesity.117 The need for
Homo sapiens to supply adequate glucose for a large brain to
metabolize in recurrent famine situations and for the female
to store sufficient fat to carry a pregnancy successfully and
feed the baby could have ensured selection of genes that
prioritized high-energy nutrients in the sparse environments
and encouraged rapid ingestion and fat storage. It would be
interesting to know whether the CNV in the salivary amylase
gene (AMY1), which affects detection of starch and associates with higher BMI, has been subject to pre-agricultural
selection. Parallel selection for rapid immune and stress
responsiveness is also possible.117 Those “survivor” genes
selected as a result of responsiveness to environmental nutrient cues could, with current OE, be predicted to increase
the prevalence of obesity. However, there is at present very
little direct evidence from genomic studies which bears on
this question. A few studies report signals of selection at
obesity susceptibility loci identified in GWAS118,119 but no
clear pattern has yet emerged. If however, as we conclude,
causative obesogenic variants are rare, unknown, and not
captured in GWAS, the detected selection signals have marginal relevance to endemic obesity and we do not yet have
the genomic data to test selection hypotheses.

Opportunity for more targeted
prevention and customized
treatment of obesity
The results of genomic studies to date have contributed very
little, if anything of immediate relevance to the prevention
and treatment of common obesity and its associated disorders.
This contrasts, in our view, with the obvious and immediate
potential implications of the well-established genetic basis for
the disorder, which have not yet been exploited in the clinical
or public health arenas. It seems to us that the failure, to date,
to explain obesity susceptibility by genomic studies is, in some
quarters, being interpreted incorrectly as questioning the overall genetic basis of the disorder. It may be that accumulation of
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causal variants would therefore amplify the genetic message,
but the time when risk information from genomic data would
be more informative than, say, family history appears to be a
long way off. Similarly, we can find no evidence that known
genomic markers are able to predict responses to currently
available treatments. Again, this contrasts with the potential for
known nongenomic risk factors, like family history, to predict
the need for and responses to interventions.120
In the future, it is probable that information from genomic
and physiological studies will identify new therapeutic targets
that ideally would avoid the side effects responsible for the
recurrent failure of drug development.40 In the short term, discovery of genomic markers that would help to identify subsets
of patients who would either respond to currently available
treatments or who are at greater or lesser risk of the common
side effects or comorbidities of obesity would be an advance.
A recent analysis found that the benefit of reduced availability
of junk food in schools was restricted to children with a family
history of overweight.120 This highlights one of the potential
benefits of genetic risk classification of individuals, but there
is much to do before genomic information provides better risk
prediction than do currently available markers such as family history. A family history of T2DM may be a particularly
powerful discriminator as it identifies a group with history of
obesity with pathogenic consequences.18,24
There is strong desire in many quarters to intervene early,
in children or in utero, in part because childhood obesity is a
strong predictor of adult obesity and its consequences. As we
now understand, this relationship reflects the shared genetic
makeup of child and adult and is unlikely to be causative. The
drive for aggressive early interventions ought to be diminished by the knowledge of the genetic basis of the disorder
and by the lack of effectiveness of past interventions and the
potential adverse consequences of interventions.49,50

Implications for enhanced patient
care such as quality of life
An acceptance by science, medicine, and the public that
common obesity is strongly heritable would in itself be a
therapeutic advance, which should lead to significant changes
to current approaches:
• Development of a more sympathetic approach to current
patient management by clinicians who would then accept
that genetic predisposition to susceptibility to the current
OE underlies the repeated failures of “will-power”.121
• Lessening of repetitive weight loss attempts undertaken
despite the inevitable regain and the personal sense of
failure that this entails.
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• Early life intervention should be undertaken only where
evidence of both benefit and lack of harm has been
demonstrated in studies. There is a real possibility of
permanent mental and physical harm if useless interventions are repeated in ever younger populations.49,50
• Similarly, public health interventions to prevent obesity
that are unsuccessful must be altered or abandoned. The
public influences on obesity are mainly in the domains
of economics and marketing, not in modifiable personal behaviors. Investment in ineffective behavioral
messages targeting obesity is futile and serves only to
maintain a false picture of the problem ignoring the
genetic element, and thereby maintaining the dominant
public51 and clinical121 view of obesity as a personal
failing.
Studies to define the condition of healthy obesity and
its maintenance will allow less intervention, and hence
increased quality of life, if no adverse associations or health
conditions are found. There are no established protective
markers yet, but a recent report of a low-frequency (1.5%)
variant in the Cyclin D2 gene, which increases body mass
but decreases diabetes risk, may be an encouraging sign122;
1.5% could represent a useful proportion of the healthy
obese (∼25%).

Conclusion
As genomic naïves, it appears to us that in the immediate
future we must aim or hope for two things:
1. Identification of points of convergence in phenotypic
pathways by better measurement and assessment of collateral links to other physiological systems. We should
not aim to personalize treatments to an individual gene,
which seems very unrealistic in this domain, and should
be targeting the effects of groups of genes by satiety
induction.
2. Identification, discrimination, and quantitation of obesogenic environmental factors and understanding how
they interact with obesogenic genetic variants to increase
their effect. There may be opportunities to counteract
personal exposures to elements of OE or to identify more
realistic targets for public health interventions.
We believe that genomic studies, which have helped to
define the genetic basis of common obesity mainly by exclusion, will in the future play an increasingly important role
in the understanding and management of obesity, but not
without parallel studies of the physiological, behavioral, and
economic influences, and especially not without the use of
more informative phenotypes than BMI.
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